methyl 3'-(benzyloxy)-[1,1'-biphenyl]-4-carboxylate | 122294-02-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3'-(benzyloxy)-[1,1'-biphenyl]-4-carboxylate
• 英文别名: Methyl 3'-(benzyloxy)[1,1'-biphenyl]-4-carboxylate；methyl 4-(3-phenylmethoxyphenyl)benzoate
• CAS: 122294-02-4
• 化学式: C₂₁H₁₈O₃
• 分子量: 318.372
• InChiKey: PLOSQZCTSHXXQD-UHFFFAOYSA-N

物化性质

• 熔点：
  105-106 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  470.1±33.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 3'-(benzyloxy)-[1,1'-biphenyl]-4-carboxylate 在 吡啶 、 sodium hydroxide 、 草酰氯 作用下， 以 乙醇 、 二氯甲烷 、 甲苯 为溶剂， 反应 38.0h， 生成 3'-(phenylmethoxy)-N-<4-(3-pyridinyl)butyl>-1,1'-biphenyl-4-carboxamide
  参考文献：
  名称：

  Biphenylcarboxamide derivatives as antagonists of platelet-activating factor

  摘要：

  A series of N-[4-(3-pyridinyl)butyl]-1,1'-biphenyl-4-carboxamides was prepared, and the compounds were evaluated for platelet-activating factor (PAF) antagonist activity in a binding assay employing washed, whole dog platelets and in vivo for their ability to inhibit PAF-induced bronchoconstriction in the guinea pig. The inclusion of a methyl group in the R configuration on the side-chain carbon adjacent to the carboxamide nitrogen atom of these derivatives resulted in a marked enhancement of potency in the binding assay for compounds unsubstituted in the biphenyl 2-position and, more importantly, in improved oral bioavailability. Previous work with related pyrido[2,1-b]-quinazoline-8-carboxamides suggests that the presence of such an alkyl group improves bioavailability by rendering the resulting compounds resistant to degradation by liver amidases. The most interesting compounds to emerge from this work are (R)-2-bromo-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]-1,1'-bi phe nyl- 4-carboxamide (33) and (R)-2-butyl-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]- 1,1'-biphenyl-4-carboxamide (40) each of which inhibits PAF-induced bronchoconstriction in the guinea pig by greater than 55%. 6 h after an oral dose of 50 mg/kg.

  DOI：

  10.1021/jm00128a025
• 作为产物：
  描述：

  3-苄氧基溴苯 、 对溴苯甲酸甲酯 生成 methyl 3'-(benzyloxy)-[1,1'-biphenyl]-4-carboxylate
  参考文献：
  名称：

  Biphenylcarboxamide derivatives as antagonists of platelet-activating factor

  摘要：

  A series of N-[4-(3-pyridinyl)butyl]-1,1'-biphenyl-4-carboxamides was prepared, and the compounds were evaluated for platelet-activating factor (PAF) antagonist activity in a binding assay employing washed, whole dog platelets and in vivo for their ability to inhibit PAF-induced bronchoconstriction in the guinea pig. The inclusion of a methyl group in the R configuration on the side-chain carbon adjacent to the carboxamide nitrogen atom of these derivatives resulted in a marked enhancement of potency in the binding assay for compounds unsubstituted in the biphenyl 2-position and, more importantly, in improved oral bioavailability. Previous work with related pyrido[2,1-b]-quinazoline-8-carboxamides suggests that the presence of such an alkyl group improves bioavailability by rendering the resulting compounds resistant to degradation by liver amidases. The most interesting compounds to emerge from this work are (R)-2-bromo-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]-1,1'-bi phe nyl- 4-carboxamide (33) and (R)-2-butyl-3',4'-dimethoxy-N-[1-methyl-4-(3-pyridinyl)butyl]- 1,1'-biphenyl-4-carboxamide (40) each of which inhibits PAF-induced bronchoconstriction in the guinea pig by greater than 55%. 6 h after an oral dose of 50 mg/kg.

  DOI：

  10.1021/jm00128a025

文献信息

• <i>meta</i> C–H Arylation of Electron-Rich Arenes: Reversing the Conventional Site Selectivity
  作者：Luo-Yan Liu、Jennifer X. Qiao、Kap-Sun Yeung、William R. Ewing、Jin-Quan Yu

  DOI：10.1021/jacs.9b07887

  日期：2019.9.18

  report the first catalytic system that effectively performs meta C-H arylation of a variety of alkoxy aromatics including 2,3-dihydrobenzofuran and chromane with exclusive meta site-selectivity, thus reversing the conventional site selectivity governed by native electronic effects. The identification of an effective ligand and modified norbornene (NBE-CO2Me), as well as taking advantage of the statistics

  在不使用导向基团的情况下控制 CH 活化的位点选择性仍然是一个重大挑战。虽然由相互排斥的吡啶型配体调节的 Pd(II) 催化剂已被证明有利于芳烃相对富电子的碳中心，但逆转选择性以有利于相对缺电子位置的钯化作用是不可能的。在这里，我们报告了第一个催化系统，该系统有效地对包括 2,3-二氢苯并呋喃和色烷在内的各种烷氧基芳烃进行间位 CH 芳基化，具有独特的间位选择性，从而逆转了由天然电子效应控制的传统位点选择性。有效配体和改性降冰片烯 (NBE-CO2Me) 的鉴定，
• Unusual polymorphism in new bent-shaped liquid crystals based on biphenyl as a central molecular core
  作者：Anna Kovářová、Svatopluk Světlík、Václav Kozmík、Jiří Svoboda、Vladimíra Novotná、Damian Pociecha、Ewa Gorecka、Natalia Podoliak

  DOI：10.3762/bjoc.10.75

  日期：——

  Bent-shaped mesogens possessing a biphenyl as a central core have been synthesized and the role of the terminal chain and the orientation of the ester as a linkage group have been investigated. For the studied molecular core we have established that both parameters play an important role for the mesomorphic properties. The polyfluoroalkyl terminal chain supports the formation of mesophases, and the introduction of a chiral lactate terminal chain destabilizes mesophases for the first type of mutual orientation of ester groups, attached to the central core. On the contrary, for the opposite orientation of esters, the terminal chain has no effect on the mesomorphic properties, and columnar phases have been found for all compounds. A unique phase sequence has been found for the mesogen with the fluorinated chain. A generalized tilted smectics, SmC_G, have been observed in a temperature interval between two different lamellar SmCP phases and characterized by X-ray and dielectric measurements. The dielectric spectroscopy data are unique and presented for the first time in the SmC_G phase providing new information about the molecular dynamics.

  具有联苯作为中心核心的弯曲形态基团已被合成，并研究了末端链和酯作为连接基团的取向。针对所研究的分子核心，我们已经确定这两个参数对向列相性质起重要作用。多氟烷基末端链支持向列相的形成，而手性乳酸酯末端链的引入破坏了第一种酯基相互取向方式附着在中心核心上的向列相。相反，对于酯基的相反取向，末端链对向列相性质没有影响，并且所有化合物都发现了柱状相。对于具有氟化链的基团，发现了独特的相序列。在两种不同的层状SmCP相之间的温度区间内观察到了广义倾斜液晶相SmC_G，并通过X射线和介电测量进行了表征。介电谱数据是独特的，并首次在SmC_G相中提供了关于分子动力学的新信息。
• Novel bicyclic hydroxamates as inhibitors of histone deacetylase
  申请人：Leahy M Ellen

  公开号：US20060058553A1

  公开（公告）日：2006-03-16

  The present invention is directed to certain bicyclic hydroxamate derivatives that are inhibitors of histone deacetylase and are therefore useful in the treatment of diseases associated with histone deacetylase activity. Pharmaceutical compositions and processes for preparing these compounds are also disclosed

  本发明涉及某些双环羟肟衍生物，它们是组蛋白去乙酰化酶的抑制剂，因此可以用于治疗与组蛋白去乙酰化酶活性相关的疾病。本发明还公开了制备这些化合物的制药组合物和过程。
• 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Yonekubo Shigeru

  公开号：US20090074738A1

  公开（公告）日：2009-03-19

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等的药物。该化合物是一种1-取代-3-(β-D-葡萄糖苷基)氮杂环化合物，其通式表示为(I)，其前药，或其药学上可接受的盐，或其水合物或溶剂化物；包含该化合物的SGLT抑制剂；包含该化合物的制药组合物和药物组合制剂。在该式中，A代表烷基或烯烃基；B代表单键，—O—，—S—或—NH—；C代表可选择取代的芳基或杂芳基；Q独立地表示氢原子或取代基结合的碳原子或氮原子。
• 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07750145B2

  公开（公告）日：2010-07-06

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等药物。它是一种1-取代-3-（β-D-葡萄糖苷基）含氮杂环化合物，代表通式（I），其前药，或其药学上可接受的盐，或其水合物或溶剂化物；含有SGLT抑制剂的化合物；含有该化合物的制药组合物。在该式中，A代表烷基或烯基；B代表单键，-O-，-S-或-NH-；C代表可选取代的芳基或杂环芳基；Q独立地表示氢原子或取代基连接的碳原子或氮原子。